On the results of an open-label single-arm study to evaluate the efficacy, safety and tolerability of acnecutan in patients suffering from severe forms of acne as well as acne resistant to other therapies

Goal: evaluation of the efficacy and safety of acnecutan in patients with severe forms of acne or if other acne treatment methods prove to be inefficient. Materials and methods: the study involved 35 patients with severe forms of acne and acne resistant to other therapies. The patients received a monotherapy with acnecutan. The efficacy and safety of this therapy were evaluated at each visit judging by the clinical picture of the disease; the severity of the disease was defined based on the count of components (such as comedones, papulopustules, nodes, dyschromias and scars). The safety of the drug was assessed based on the data on adverse and unforeseen events taking into account subjective (patient’s complaints) and objective (total blood count, urine test, blood biochemistry) indices. Results: against the background of the course of treatment with acnecutan, all patients who participated in the study clinical achieved remission. Conclusion: acnecutan is a highly efficient drug for the treatment of severe forms of acne or acne resistant to other treatments.